% | $
Quotes you view appear here for quick access.

Opko Health, Inc. Message Board

  • juniorace2002 juniorace2002 Nov 11, 2013 12:44 PM Flag

    OPK Earnings Out

    Highlights -

    OPKO Announces Third Quarter 2013 Financial and Operating Highlights

    Revenue Nearly Doubled to $20.6 million for the Third Quarter 2013; Increased More Than Twofold to $75.8 million for the First Nine Months of 2013
    Initiation of Pivotal Clinical Validation Study for 4Kscore™
    Enrollment in Our Pivotal Rayaldy™ Clinical Trials Surpassed 75% Completion; Top-Line Data Expected in Mid-2014
    Continuing Progress Toward Completion by TESARO of Rolapitant Phase 3 Clinical Trials; Two of TESARO's Phase 3 trials of Rolapitant Are Now Fully Enrolled, Top-line Data Expected at Year End. TESARO Also Initiated an Open-Label, Dose-Finding and Escalation Study to Evaluate Intravenous (IV) Formulation of Rolapitant
    Final Marketing Authorization for Citicoline Products in Spain
    Completed Acquisition of PROLOR Biotech
    Strategic Investment in Biotechnology Company Engaged in the Development of a New Generation of Antibodies
    Strategic Investment in Clinical Stage Biopharmaceutical Company Focused in the Development of Oncology Therapeutics
    New Listing on Tel Aviv Stock Exchange
    Neovasc, an OPKO Investment Portfolio Company, Reported That the Neovasc Reducer™ Achieved Primary Endpoint in COSIRA Trial, Significantly Improving Function in Patients with Refractory Angina
    Cash and Marketable Securities at $180.8 million as of September 30, 2013

    Sentiment: Strong Buy

9.80-0.54(-5.22%)May 4 4:02 PMEDT